Aflibercept for pigment epithelial detachment for previously treated neovascular age-related macular degeneration

详细信息    查看全文

• 作者：James C. Major Jr. ; MD ; PhD^* ; Charles C. Wykoff ; MD ; PhD^* ; ^{ccwmd@houstonretina.com" class="auth_mail" title="E-mail the corresponding author} ; Daniel E. Croft ; BA^&dagger ; ; Rui Wang ; BA^&dagger ; ; Angeline F. Mariani ; BA^&dagger ; ; Anna E. Lehmann ; BA^&dagger ; ; David M. Brown ; MD^*
• 刊名：Canadian Journal of Ophthalmology / Journal Canadien d'Ophtalmologie
• 出版年：2015
• 出版时间：October 2015
• 年：2015
• 卷：50
• 期：5
• 页码：373-377
• 全文大小：649 K

文摘

Assess the efficacy of intravitreal aflibercept on pigment epithelial detachments (PED) associated with previously treated patients with neovascular age-related macular degeneration (AMD).

Design

Retrospective study.

Participants

Sixty eyes.

Methods

Patients with persistent PED who were treated with intravitreal aflibercept (2.0 mg) with ≥2 previous injections of bevacizumab (1.25 mg) or ranibizumab (0.5 mg) were analyzed.

Results

Mean number of prior injections was 24.8 during a mean of 32 months of management (range 3-77 months). Baseline mean PED height was 258 µm (range 80-687 µm), which decreased at 1, 6, and 12 months upon switching to aflibercept to 226 µm (–14%, range 34-701 µm), 215 µm (–18%, range 0-666 µm), and 208 µm (–22%, range 0-752 µm), respectively. The majority of eyes experienced a decrease in PED height after switching to aflibercept: 50/58 (86%), 38/47 (81%), and 37/47 (79%) at months 1, 6, and 12, respectively. Reduction in PED height was weakly correlated with improved visual acuity (R² = 0.11).

Conclusions

Intravitreal aflibercept resulted in significant reduction in PED height in previously treated eyes with neovascular AMD.